Sionna Therapeutics, Inc.’s (NASDAQ:SION) Quiet Period Set To End on March 19th

Sionna Therapeutics’ (NASDAQ:SION) quiet period will expire on Wednesday, March 19th. Sionna Therapeutics had issued 10,588,233 shares in its public offering on February 7th. The total size of the offering was $190,588,194 based on an initial share price of $18.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SION shares. TD Cowen started coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating on the stock. Stifel Nicolaus started coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $32.00 price objective on the stock. Finally, Guggenheim started coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $45.00 price objective on the stock.

Sionna Therapeutics Price Performance

SION stock opened at $14.98 on Friday. Sionna Therapeutics has a 52 week low of $13.20 and a 52 week high of $25.19.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.